Stock 1952 EVEREST MEDICINES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News Everest Medicines Limited

Equities

1952

KYG3224E1061

Market Closed - Hong Kong S.E.
Other stock markets
 04:09:09 2024-04-25 am EDT 		5-day change 1st Jan Change
24.1 HKD +2.55% Intraday chart for Everest Medicines Limited +5.24% +15.31%
05:11am Everest Medicines' Loss Widens in 2023 MT
Mar. 28 Everest Medicines Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Everest Medicines' Loss Widens in 2023
MT
Everest Medicines Limited Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023
AQ
Transcript : Everest Medicines Limited, 2023 Earnings Call, Mar 27, 2024
Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer
AQ
Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer
CI
Everest Medicines to Announce Full-Year 2023 Financial Results on March 28, 2024
AQ
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
PR
Everest Medicines' Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis
PR
Everest Medicines Licensing Partner Venatorx Pharmaceuticals Announces Publication of Positive Results from Cefepime-Taniborbactam's Phase 3 CERTAIN-1 Study in New England Journal of Medicine
AQ
Calliditas Year-end report, January - December 2023
AQ
Everest Medicines Announces Termination of Collaboration Agreements with Providence
AQ
Everest Medicines Terminates Collaboration with Canada’s Providence for mRNA COVID-19 Vaccines
MT
Everest Medicines Limited Announces Board Changes
CI
Everest Medicines Announces 2023 Revenue Expected to be Between RMB124 Million and RMB126 Million
AQ
Everest Foresees Surge in 2023 Revenue
MT
Everest Medicines Limited Provides Earning Guidance for the Year Ended 31 December 2023
CI
Everest Medicines Limited Announces Directorate Changes
CI
Everest Medicines Announces New Drug Application Acceptance of Nefecon® in Taiwan for the Treatment of Primary IgA Nephropathy in Adult Patients
CI
Everest Medicines Partner Calliditas Therapeutics Announces Nefecon the Only FDA-approved Treatment for IgA Nephropathy to Significantly Slow Kidney Function Decline
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1952 Stock
  4. News Everest Medicines Limited